EGFR and non-small cell lung carcinoma: Together, these results show that EGFR and DR4/5 are upregulated in NSCLC both in patient samples and in vivo mouse NSCLC models, and thus represent suitable candidates to investigate the therapeutic potential of therapies targeted at these receptors.